Cargando…
‘Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM’ – Author's reply
Autores principales: | Broman, Niklas, Feuth, Thijs, Oksi, Jarmo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250883/ https://www.ncbi.nlm.nih.gov/pubmed/35798145 http://dx.doi.org/10.1016/j.cmi.2022.06.028 |
Ejemplares similares
-
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study
por: Broman, Niklas, et al.
Publicado: (2022) -
Re: Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM
por: Klopfenstein, Timothée, et al.
Publicado: (2022) -
Association of human myxovirus resistance protein A with severity of COVID-19
por: Lehtinen, Otto, et al.
Publicado: (2022) -
Rapid implementation of home oxygen treatment and remote monitoring for COVID-19 patients at the verge of the Omicron wave in Turku, Finland
por: Hänninen, Janne, et al.
Publicado: (2023) -
Authors’ Reply to: Tocilizumab, Adipokines and Severe Complications of COVID-19
por: Liu, Bin, et al.
Publicado: (2020)